Development of transgenic Caenorhabditis elegans expressing human transthyretin as a model for drug screening
Familial amyloid polyneuropathy is a hereditary systemic amyloidosis caused by a mutation in the transthyretin (TTR) gene. Amyloid deposits in tissues of patients contain not only full-length TTR but also C-terminal TTR fragments. However, in vivo models to evaluate the pathogenicity of TTR fragment...
Gespeichert in:
Veröffentlicht in: | Scientific reports 2018-12, Vol.8 (1), p.17884-13, Article 17884 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Familial amyloid polyneuropathy is a hereditary systemic amyloidosis caused by a mutation in the transthyretin (TTR) gene. Amyloid deposits in tissues of patients contain not only full-length TTR but also C-terminal TTR fragments. However,
in vivo
models to evaluate the pathogenicity of TTR fragments have not yet been developed. Here, we generated transgenic
Caenorhabditis elegans
strains expressing several types of TTR fragments or full-length TTR fused to enhanced green fluorescent protein in the body wall muscle cells and analyzed the phenotypes of the worms. The transgenic strain expressing residues 81–127 of TTR, which included the β-strands F and H, formed aggregates and caused defective worm motility and a significantly shortened lifespan compared with other strains. These findings suggest that the C-terminal fragments of TTR may contribute to cytotoxicity of TTR amyloidosis
in vivo
. By using this
C
.
elegans
model system, we found that (−)-epigallocatechin-3-gallate, a major polyphenol in green tea, significantly inhibited the formation of aggregates, the defective motility, and the shortened lifespan caused by residues 81–127 of TTR. These results suggest that our newly developed
C
.
elegans
model system will be useful for
in vivo
pathological analyses of TTR amyloidosis as well as drug screening. |
---|---|
ISSN: | 2045-2322 2045-2322 |
DOI: | 10.1038/s41598-018-36357-5 |